Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2026 Vol. 4 > No. 2 > 100200
Next Article Previous Article
GUIDELINE SNAPSHOT   Open Access     Cite

Precision management of acute myeloid leukemia: A unified guideline of international and regional standards

  • 1.

    Department of Basic Medicine, School of Medicine, Foshan University, Foshan 528000, China

  • 2.

    Department of Pediatric Hematology and Oncology, Children’s Hospital of Chongqing Medical University, Chongqing 400014, China

  • 3.

    Precision Oncology and Intelligent Theranostics Laboratory, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Children and Adolescents' Health and Diseases, Children’s Hospital of Chongqing Medical University, Chongqing 400014, China

  • 4.

    These authors contributed equally

More Information
  • Corresponding author: youhua307@163.com
  • Received Date:  October 09, 2025
    Accepted Date:  March 02, 2026
    Published Online:  March 03, 2026
The Innovation Medicine  4(2),  https://doi.org/10.59717/j.xinn-med.2026.100200  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Gangat N. and Tefferi A. (2025). Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days. Blood Cancer J. 15:56. DOI:10.1038/s41408-025-01270-4

    View in Article CrossRef Google Scholar

    [2] DiNardo C.D., Marvin-Peek J., Loghavi S., et al. (2025). Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitor for intensive chemotherapy-ineligible patients with isocitrate dehydrogenase-mutated AML. J. Clin. Oncol. 43:2692−2699. DOI:10.1200/JCO-25-00640

    View in Article CrossRef Google Scholar

    [3] Wang E.S., Montesinos P., Foran J., et al. (2025). Ziftomenib in relapsed or refractory NPM1-mutated AML. J. Clin. Oncol. 43:3381−3390. DOI:10.1200/JCO-25-01694

    View in Article CrossRef Google Scholar

    [4] Issa G.C., Aldoss I., Thirman M.J., et al. (2025). Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J. Clin. Oncol. 43:75−84. DOI:10.1200/JCO.24.00826

    View in Article CrossRef Google Scholar

    [5] Sun W. and Huang X. (2024). CAR-T cell therapy shines as a beam of hope in the fight against acute leukemia. Holist. Integ. Oncol. 3. DOI:10.1007/s44178-024-00117-5

    View in Article Google Scholar

    • Cited by

  • Cite this article:

    Xun Y., Yang H., Shen Y., et al. (2026). Precision management of acute myeloid leukemia: A unified guideline of international and regional standards. The Innovation Medicine 4:100200. https://doi.org/10.59717/j.xinn-med.2026.100200
    Xun Y., Yang H., Shen Y., et al. (2026). Precision management of acute myeloid leukemia: A unified guideline of international and regional standards. The Innovation Medicine 4:100200. https://doi.org/10.59717/j.xinn-med.2026.100200

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(3017) PDF downloads(5086)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.